Journal of Infection and Chemotherapy

, Volume 11, Issue 5, pp 259–261

Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan


DOI: 10.1007/s10156-005-0402-2

Cite this article as:
Kobayashi, Y. J Infect Chemother (2005) 11: 259. doi:10.1007/s10156-005-0402-2


S-4661 is a methylcarbapenem antibiotic newly developed in Japan. We evaluated the combined actions of carbapenems, including S-4661 and vancomycin or teicoplanin, against 27 strains of methicillin-resistant Staphylococcus aureus (MRSA) isolated from the blood of patients admitted to Keio University Hospital, using the checkerboard technique. The minimum inhibitory concentrations (MICs) were determined by the Mueller-Hinton agar method. Most of the strains were highly resistant to carbapenems. Synergy with S-4661, panipenem, meropenem or imipenem, and vancomycin was detected against 92% of the strains tested. Synergy with S-4661, panipenem, meropenem or imipenem, and teicoplanin was detected against 74% of the strains tested. The results of our study suggest that combination therapy of vancomycin or teicoplanin with any of S-4661, panipenem, meropenem, or imipenem would be effective for severe infections due to MRSA strains that are resistant to carbapenems.

Key words

Synergy MRSA S-4661, a new carbapenem antibiotic Vancomycin Teicoplanin 

Copyright information

© Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases 2005

Authors and Affiliations

  1. 1.Division of Clinical Microbiology, Department of Clinical LaboratoriesKeio University HospitalTokyoJapan

Personalised recommendations